SUSPEND Trial | Tamsulosin for Kidney Stones Explained

SUSPEND Trial | Tamsulosin for Kidney Stones Explained

Tamsulosin for kidney stones is one of the most commonly prescribed therapies for ureteral stones — but does it actually help? In this episode of This Is Why with Dr. Busti, we break down the landmark SUSPEND trial and explain why the answer depends on the patient, the stone size, and the clinical context. This Is Why many clinicians changed how they approach medical expulsive therapy after SUSPEND. But the real lesson is not simply whether to use tamsulosin — it’s understanding which patients are most likely to benefit and why later evidence refined the conversation. Dr. Busti walks through the trial design, the limitations of pragmatic endpoints, subgroup nuance, and how later studies reshaped guideline recommendations for distal ureteral stones. Topics Covered: - Why the SUSPEND trial changed kidney stone management - Medical expulsive therapy explained - How tamsulosin works in ureteral stones - Why stone size matters clinically - Distal vs proximal ureteral stones - Understanding the ceiling effect in clinical trials - Why most stones ≤5 mm pass spontaneously - Evidence for alpha blockers in larger stones - CT-confirmed stone passage vs intervention outcomes - How later trials refined the evidence - Current EAU, NICE, and AUA guidance - Which patients may benefit from tamsulosin - Why nifedipine fell out of favor - Applying evidence at the bedside - Patient selection in evidence-based medicine The goal = make medical education easy and clinically relevant. 👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/tamsulosin-kidney-stones-suspend-trial 👉 Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources Chapter Table of Contents 00:00 - Introduction 02:02 - Why the SUSPEND Trial Was Needed 04:00 - Study Design & Primary Outcome 07:09 - Trial Results 09:15 - Interpreting the Findings 11:02 - Later Evidence & Meta-Analyses 13:34 - Guidelines & Clinical Recommendations 15:52 - Bedside Application and Practice Takeaways 18:23 - Conclusion 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #Tamsulosin #KidneyStones #MedicalExpulsiveTherapy #SUSPENDTrial #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Epistaxis Explained Why Nosebleeds Happen | Dr. Busti

Epistaxis explained by Dr. Busti. In this episode on This Is Why, we break down why epistaxis happens, how clinicians think through causes of bleeding, and why the location of bleeding matters clinically. Dr. Busti explains anterior vs posterior epistaxis, common risk factors, medication-related bleeding, vascular anatomy, and when recurrent nosebleeds may signal a more serious underlying condition. This episode connects anatomy, physiology, pathology, and clinical reasoning so healthcare professionals can better understand the “why” behind epistaxis and nosebleed management. Topics Covered: - What epistaxis means clinically - Why nosebleeds happen - Dryness and nasal mucosal irritation - Trauma and nose picking - Inflammation and upper respiratory infections - Anticoagulants antiplatelets and NSAIDs - Intranasal steroids and cocaine exposure - Bleeding disorders and thrombocytopenia - Hereditary hemorrhagic telangiectasia HHT - Leukemia liver disease and vasculitis - Kiesselbach plexus anatomy - Anterior vs posterior epistaxis - Why posterior bleeds are more concerning - Risk factors for recurrent epistaxis - Initial management principles for nosebleeds - Why anatomy changes treatment decisions 👉 Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources Chapter Table of Contents 00:00 - Introduction 01:11 - Pop Culture vs Clinical Reality 02:55 - Definition of Epistaxis 04:17 - Common Causes of Nosebleeds 07:42 - Medications & Bleeding Risk 09:00 - Systemic Diseases & Structural Causes 11:36 - Nasal Blood Supply & Kiesselbach's Plexus 13:11 - Anterior vs Posterior Epistaxis 15:04 - Treatment & Management of Epistaxis 16:21 - Conclusion 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #Epistaxis #Nosebleed #AnteriorEpistaxis #PosteriorEpistaxis #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

Effect Size (Relative Risk (RR), Odds Ratio (OR), NNT/NNH) Made Simple

Effect size (Relative risk vs odds ratio vs hazard ratio & NNT and NNH explained — This Is Why understanding these concepts is essential for interpreting clinical trials with Dr. Busti. In this episode of This Is Why, Dr. Busti breaks down relative risk (RR), odds ratios (OR), absolute risk reduction (ARR), absolute risk increase (ARI), number needed to treat (NNT), and number needed to harm (MMH) in a way that connects directly to real clinical decision-making. This Is Why learning the “why” behind these calculations helps you move beyond memorization and actually apply evidence to patient care. You’ll learn how to interpret whether a treatment increases or decreases risk, how to calculate and understand number needed to treat (NNT), and how to avoid common mistakes—like misinterpreting percentages or confusing statistical vs clinical meaning. Dr. Busti also walks through practical examples, including antihypertensive side effects, aspirin for MI prevention, and statin therapy, to show how these metrics influence real-world decisions. Topics Covered: - Definition of relative risk (risk ratio) - When to use relative risk (RR) vs odds ratio (OR) vs hazards ratio (HR) - Prospective vs retrospective study design - Interpreting RR - Confidence intervals and statistical significance - Relative risk increase vs reduction - Absolute risk reduction (ARR) explained - Number needed to treat (NNT) & Number needed to harm (NNH) calculations - Clinical vs statistical interpretation of risk - Applying evidence to cost and patient outcomes The goal = make medical education easy and clinically relevant. 👉 Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #relativerisk #oddsratio #nnt #ebm #Dr Busti  Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

D-Dimer Explained: When Suspected DVT Needs Ultrasound

D-dimer explained for DVT evaluation. This Is Why healthcare professionals must understand what an elevated D-dimer actually means before jumping to conclusions. Dr. Busti walks through a common deep vein thrombosis scenario and explains why compression ultrasonography—not automatic anticoagulation—is the correct next step when DVT is suspected. Many learners incorrectly assume that an elevated D-dimer confirms a clot. Others memorize algorithms without understanding the clinical reasoning behind them. In this episode, Dr. Busti breaks down Wells score interpretation, pretest probability, D-dimer limitations, and how clinicians should approach suspected DVT in real-world practice. Whether you're preparing for boards, rotations, residency, or clinical practice, this episode focuses on understanding the "why" behind thrombosis evaluation so you can confidently apply the "how." Topics Covered: - Understanding DVT pretest probability - Interpreting the Wells-DVT score - What D-dimer actually measures - Why elevated D-dimer does not confirm DVT - Negative predictive value and rule-out testing - Age-adjusted versus conventional D-dimer thresholds - When compression ultrasonography is indicated - Why anticoagulation is not always the next step - Common board exam traps in DVT evaluation - Clinical reasoning for suspected venous thromboembolism The goal = make medical education easy and clinically relevant. 👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/d-dimer-explained-suspected-dvt-ultrasound-exam-question 👉 Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #DVT #DDimer #WellsScore #DeepVeinThrombosis #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

NINDS Trial Explained Stroke Thrombolysis Risks and Benefits

Stroke thrombolysis changed emergency neurology forever—but understanding why the NINDS trial mattered is what transforms memorization into clinical decision-making. In this episode of This Is Why with Dr. Busti, we break down the landmark NINDS rt-PA trial that established alteplase as a treatment for acute ischemic stroke and explore the real-world balance between functional recovery and intracerebral hemorrhage risk. Dr. Busti explains how to interpret the trial beyond headlines by walking through the study design, inclusion criteria, outcomes, NNT and NNH calculations, odds ratios, bleeding risk, and the evolution of thrombolytic therapy from alteplase to tenecteplase. This episode also contextualizes modern AHA/ASA recommendations and what clinicians should actually say during bedside risk-benefit discussions with patients and families. This Is Why medical education focuses on understanding the “why” behind clinical decisions so healthcare professionals can apply evidence with confidence and clarity. Topics Covered: - NINDS rt-PA trial explained - Alteplase for acute ischemic stroke - Stroke thrombolysis risks and benefits - Functional recovery vs hemorrhage risk - NNT and NNH interpretation - Odds ratio vs absolute risk - Tenecteplase vs alteplase - Modern stroke thrombolysis guidelines - Shared decision-making in stroke care - Why early reperfusion matters The goal = make medical education easy and clinically relevant. 👉 Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/ninds-trial-stroke-thrombolysis-risks-benefits 🎥 Watch other videos referenced in this episode! P-Value: https://youtu.be/ibl85Flpm94 Alpha Value Explained: https://youtu.be/Fmu4HwaGrtU Power Analysis - Type II Error Risk: https://youtu.be/zn9q9E1IOoc 👉 Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos  - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources Chapter Table of Contents 00:00 - Introduction 01:46 - NINDS Trial (1995) 04:40 - Trial Design, Inclusion & Exclusion Criteria 06:38 - Part 1: The Negative 24-Hour Endpoint Explained 11:28 - Part 2: Functional Outcomes That Changed Practice 13:45 - NNT, NNH & Explaining Risk to Patients 19:18 - One-Year Outcomes & Interpreting Odds Ratios Correctly 22:09 - Later Evidence, Meta-Analyses & Expanded Treatment Windows 25:30 - Tenecteplase vs Alteplase & Modern Stroke Practice 28:17 - Conclusion 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #AcuteIschemicStroke #NINDSTrial #StrokeThrombolysis #Alteplase #Tenecteplase #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.